Spots Global Cancer Trial Database for Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State

Official Title: Phase 1 Single Dose 2-Way Crossover Comparative Bioavailability Study Of Two Oral Formulations Of MGCD265 In Healthy Male And Female Subjects - Fasting State

Study ID: NCT01930006

Conditions

Advanced Malignancies

Interventions

MGCD265

Study Description

Brief Summary: In this study two MGCD265 oral formulations at dose level of 100 mg are administered to healthy male and female subjects under fasting conditions.

Detailed Description: The objective of this study is to compare the rate and extent of absorption of two MGCD265 oral formulations at a dose level of 100 mg administered to healthy male and female subjects under fasting conditions.